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Multiple myeloma is an incurable hematological malignancy derived from B 
cells, and characterized by bone destruction and multiple organ dysfunctions. 
CD137 and its ligand are members of the Tumor Necrosis Factor (TNF) Receptor 
and TNF superfamilies, respectively. CD137 enhances proliferation and survival 
in healthy B cells. Since CD137 can be expressed as a neoantigen by certain B 
cell lymphomas we hypothesized that CD137 may act as a growth factor for B 
cell lymphomas. Surprisingly, we found that CD137 has the opposite effects in 
multiple myeloma (MM) cells, where it inhibits proliferation and induces cell 
death by apoptosis. In contrast, CD137 does not significantly affect or enhance 
proliferation or survival in non-MM B cell lymphoma lines. Further, secretion of 
IL-6 and IL-8 is also enhanced in MM but not in non-MM cell lines in response to 
CD137. A selective elimination of malignant B cells in MM patients by CD137 
could help to slow down disease progression and reduce the doses (and hence side 
effects) in conjunction with conventional treatment regimes. 
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1.1 MULTIPLE MYELOMA 
Multiple myeloma (MM) is a malignancy of terminally differentiated plasma cells 
that primarily reside at multiple sites in the bone marrow, as well as, at the 
extramedullary sites in the later stages of the disease. It is characterized by the 
excessive secretion of monoclonal immunoglobulins (IgG, IgA, IgD, or IgE) into 
the serum and/or urine by monotypic plasma cells (Kuehl and Bergsagel, 2002). 
Bone destruction is frequently caused by the intricate interactions that occur 
between the myeloma cells and bone-marrow microenvironment (Kyle and 
Rajikumar, 2004), leading to the activation of signaling pathways stimulating 
tumor growth, and ultimately resulting in a multitude of symptoms and organ 
dysfunction, including bone pain, fractures, hypercalcemia, renal failure, anaemia, 
and an increased susceptibility to infections (Bataille et al., 1995; Bommert et al., 
2006). 
 
MM accounts for 20% of all new hematological malignancies, making it the 
second most prevalent blood cancer (Selina, 2003). Epidemiology indicates both 
an increasing incidence and earlier age of onset for the disease (Chen-Kiang, 
2005), with an average prognosis of approximately 33 months (Piazza et al., 
2007). Treatments currently available, including the administration of drugs like 
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thalidomide, bortezomib, lenalidomide, have only resulted in an improvement in 
the overall survival of patients (Trudel et al., 2007, Palumbo et al., 2009), with no 
cure currently in sight. Even stem cell transplantation, which has been shown to 
provide long-term remission, suffers from both an increased treatment-related 
mortality, and a high rate of relapse (Bensinger, 2004). 
 
Despite advances in MM therapy, it remains an incurable hematological 
malignancy characterized by frequent early responses inevitably followed by 
treatment relapse. Relapses tend to result in progressively shorter response 
durations, with higher proliferative fractions and lower apoptotic rates, 
underscoring the emergence of drug resistance, hence contributing to the majority 
of death of MM patients, with median survival time ranges from six to nine 
months (Richardson et al., 2007). While unprecedented response rates have been 
achieved via combination therapy with the immunomodulatory drug thalidomide, 
proteasome inhibitor bortezomib, with traditional chemotherapeutic drugs like 
dexamethasone (Trudel et al., 2007, Palumbo et al., 2009), relapse rates remain 
universal and are the reason why alternative therapeutic strategies must be 
developed. Therefore, an approach that allows targeting and selective killing of 
cancerous MM cells remains highly desirable. 
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1.3 GENETICS OF MULTIPLE MYELOMA 
 
MM presents complex heterogenous cytogenetic abnormalities, with the majority 
of patients exhibiting hyperdiploid karyotypes (Smadja et al., 1998). The usage of 
interphase fluorescence in situ hybridization (FISH) has also led to the observance 
of other forms of aneuploidy, such as patients with hypoploid, near-diploid, 
pseudodiploid or near-tetraploid chromosome numbers, with the rearrangement of 
the IgH gene, trisomy 1q, and 13q deletion, being the most frequent chromosomal 





Figure 1. Molecular pathogenesis of myeloma: multiple oncogenic events. 




While one of the strongest predictors of MM disease outcome is the 
t(4;14)(p16;q32) genetic marker (Keats et al., 2006), myeloma pathogenesis itself 
relies upon multiple oncogenic events which are detailed in Figure 1. As B cells 
are inherently genetically unstable, due to the many DNA breaks necessary for 
maturation, genetic alterations at 14q32 in the Ig heavy-chain site frequently 
occur. These lead to errors in switch recombination or somatic hypermutation, 
resulting in secondary Ig translocations which aid in MM progression (Kuehl and 
Bergsagel, 2002).  
 
Another late stage progression event that occurs is the translocation of the 
prominent oncogene c-MYC, resulting in an enhanced proliferation of the tumor. 
Aberrant methylation of tumor suppressor genes like p16, SHP1, and E-cadherin 
might also be involved in the progression of monoclonal gammopathy of 
undetermined significance (MGUS), the pre-malignant lesion of MM, to full-
fledged multiple myeloma (Chim et al., 2007). Although MGUS is now easily 
diagnosed by a simple blood test, the prevention of progression to malignancy, or 
even prediction of when the tumor turns malignant, is still not possible with 





1.3 BIOLOGY OF MULTIPLE MYELOMA 
The bone marrow microenvironment, consisting of extracellular matrix (ECM) 
proteins, bone marrow stromal cells (BMSC), vascular endothelial cells, 
osteoclasts, and lymphocytes, is believed to play an important role in the homing, 
proliferation and terminal differentiation of myeloma cells (Kibler et al., 1998). It 
is this direct physical interaction of the MM cells with the BMSCs, within the 
bone marrow microenvironment, depicted in Figure 2, that leads to the activation 
of various signaling pathways, and the secretion of numerous cytokines and 
growth factors. 
 
Figure 2. The bone marrow microenvironment in multiple myeloma. 
Solid arrows reflect well-defined interactions while dashed lines reflect poorly 
defined interactions. a) A normal plasma cell. b) A multiple myeloma tumor cell 
and its interactions with five types of BMSCs. The sizes of the circles reflect 
apparent relative changes in the number and/or activity of the BMSCs. Diagram 
adapted from Kuehl and Bergsagel (2002). 
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Transforming growth factor-beta (TGF-β) is one of these cytokines, and is 
observed in high levels in multiple myeloma patients. This in turn induces 
interleukin-6 (IL-6) secretion, a pivotal MM growth factor (Krytsonis et al., 1998; 
Cook et al., 1999; Hayashi et al., 2004). Various studies have consistently 
demonstrated that stimulation of IL-6 dependent signaling pathways, by 
oncogenic mutations and the bone marrow microenvironment, not only protect 
MM cells from apoptosis induced by different stimuli (Bommert et al., 2006; 
Barille et al., 2000), but also markedly increased the spontaneous proliferation in 
some MM lines by as much as 151% (Kovacs, 2006).  
 
 
Figure 3. Essential cytokines in the proliferation and survival of MM cells. 
Diagram adapted from Van De Donk et al. (2005). 
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Other cytokines that are upregulated upon the binding of the myeloma cells to 
BMSCs include IL-8, vascular endothelial growth factor (VEGF), insulin-like 
growth factor (IGF-1), tumor necrosis factor α, and stroma-derived factor-1. 
These cytokines are thought to aid in proliferation, angiogenesis, drug resistances, 
upregulation of adhesion molecules, and the induction of an immunocompromised 
status (Shapiro et al., 2001; Sirohi and Powles, 2004; Pellegrino et al., 2005), but 
most importantly, they also induce IL-6 production from BMSCs, establishing a 
potent autocrine feedback loop that promotes tumor progression in the bone 
marrow (Van De Donk et al., 2005), as depicted in Figure 3. 
 
While interaction with the ECM may be the reason why plasma cells are 
specifically retained in the bone marrow, it is the actions of adhesion molecules, 
like H-CAM, VLA-4, ICAM-1, N-CAM, and LFA-3, which mediate the homing 
of myeloma cells as well as adhesion to bone marrow stromal cells (Teoh and 
Anderson, 1997; Cook et al, 1997). These adhesion molecules also play an 
important role in the regulation of MM cell growth and survival within the bone 
marrow microenvironment, tumor cell egress form the bone marrow with the 
development of plasma cell leukemia (PCL), and lastly, metastatic seeding at 




1.4 DIAGNOSIS AND STAGING OF MULTIPLE MYELOMA 
Patients who present with unexplained anemia, kidney dysfunction, high 
erythrocyte sedimentation rate (ESR) and serum protein, are usually asked to 
undergo blood and urine protein electrophoresis, so as to allow detection of the 
presence of Bence Jones protein, a urinary paraportein composed of free light 
chains. As this paraprotein is an abnormal immunoglobulin produced by the 
tumor, quantitative measurements are required to establish a diagnosis and in 
disease monitoring, although in very rare cases, the myeloma may be of a non-
secretory nature (Kyle and Rajkumar, 2009). 
 
Once a preliminary diagnosis of multiple myeloma has been arrived at, additional 
workup tests usually follow, such as, radiological skeletal bone surveys whereby a 
series of X-rays of the skull, axial skeleton, and proximal long bones are taken. 
Myeloma activity may manifest as lytic lesions, where resorption of local bone 
mass occurs, or punched-out lesions on the skull. A more sensitive alternative to 
the simple X-ray, is magnetic resonance imaging (MRI), which may supersede the 
skeletal survey. A bone marrow biopsy is also usually performed in order to 
estimate the percentage of bone marrow occupied by plasma cells (Kyle and 




Lastly, immunohistochemistry and cytogenetic analysis may also be undertaken, 
to detect myeloma cells which are typically CD19-, CD38+, CD45-, CD56+, 
CD138+, as well as, to provide prognostic information. A standardized diagnostic 
criteria, as detailed in Table 1, was created in 2003 by the International Myeloma 
Working Group, for symptomatic myeloma, asymptomatic myeloma and MGUS, 
as well as other related conditions (Kyle and Rajkumar, 2009).  
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Table 1. Diagnostic criteria for multiple myeloma  
 Symptomatic myeloma Asymptomatic myeloma MGUS 
Serum paraprotein Present > 30 g/L < 30 g/L 
Clonal plasma cells 
(on bone marrow biopsy) 
> 10% > 10% < 10% 
Evidence of end-organ 
damage 
 
1. Hypercalcemia  
(corrected calcium >2.75 mmol/L) 
 
2. Renal insufficiency  
(attributable to myeloma) 
 
3. Anemia  
(haemoglobin <10 g/dL) 
 
4. Bone lesions  
(lytic lesions, or osteoporosis) 
 
5. Frequent severe infections  




7. Hyperviscosity syndrome 
No myeloma-related organ 
or tissue impairment 
No myeloma-related organ 
or tissue impairment 
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Traditionally, MM patients have been staged according to the Durie-Salmon 
system, and although, some doctors still use this system, newer diagnostic 
methods are rendering it obsolete. Published by the International Myeloma 
Working Group in 2005, the International Staging System (ISS) for multiple 
myeloma relies mainly on the detection of levels of albumin and beta-2-
microglobulin in the blood (Greipp et al., 2005). As detailed in Table 2, this 
system divides cases of myeloma based only on these levels. 
 
Table 2. International Staging System for multiple myeloma 
 Stage I Stage II* Stage II* Stage III 
Serum beta-2 
microglobulin < 3.5 mg/L < 3.5 mg/L  3.5 -5.5 mg/L > 5.5 mg/L 
Albumin > 3.5 g/L < 3.5 g/L - - 
Median 
survival 62 months 44 months 44 months 29 months 
*Not stage I or II 
 
1.5 STRUCTURE AND EXPRESSION OF HUMAN CD137 
CD137 (also known as 4-1BB, induced by lymphocyte activation) is a cytokine 
receptor, that belongs to the tumor necrosis factor receptor (TNFR) superfamily. 
It was first identified in the murine system, in 1989, by screening of concanavalin 
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A-activated T cells (Kwon & Weissman, 1989). Isolation of its human 
homologue, from activated human T lymphocytes, was subsequently 
accomplished in 1993 (Schwarz et al., 1993). 
 
The gene encoding human CD137 is located on chromosome band 1p36, 
alongside four other members of the TNFR superfamily; CD30, OX40, TNFR-2 
and TRAMP/Apo3. The CD137 protein has a calculated molecular mass of 27 
kDa, and consists of 255 amino acids (aa). The first 17 aa form a signal peptide, 
while the subsequent 169 aa comprise the extracellular domain. The 
transmembrane and cytoplasmic domains, which is essential for cellular signal 
transduction, are composed of the next 27 aa and last 42 aa, respectively (Schwarz 
et al., 1997). CD137 exists either as a type I transmembrane glycoprotein with 
three cysteine-rich motifs in the extracellular domain (Mallett and Barclay, 1991; 
Schwarz et al., 1993), or as a soluble protein, that is produced from a mRNA 
splice variant (Setareh et al., 1995; Michel et al., 1998). 
 
CD137 is present on the surface of primary T lymphocytes, where its expression 
is strictly activation dependent (Schwarz et al., 1995). Dendritic cells (DC), 
natural killer (NK) cells, monocytes, and follicular dendritic cells (FDC) in 
germinal centres, are other examples of immune cells that also express CD137 
(DeBenedette et al., 1995; Melero et al., 1998; Schwarz et al., 1995; Wilcox et 
al., 2002; Heinisch et al, 2000; Heinisch et al., 2001; Pauly et al., 2002). CD137 
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may also be expressed at sites of inflammation, by vascular endothelial cells 
lining the walls of blood vessels (Drenkard et al., 2007), as well as, by some 
malignant tumors, in particular, Reed-Sternburg cells in Hodgkin's lymphoma, 
chronic lymphocytic leukemia (CLL), osteosarcoma, rhabdomyosarcoma, and 
pancreatic cancer (Broll et al., 2001; Lisignoli et al., 1998; Ringel et al., 2001; 
personal communication, Schwarz H).  
 
1.6 CO-STIMULATORY SIGNALLING EFFECTS OF CD137 
CD137 delivers potent co-stimulatory signals to activated T lymphocytes, acting 
as an important survival factor, by maintaining cellular division and facilitating 
differentiation into effector and memory cells (Kim et al., 1998; Takahashi et al., 
1999; Hurtado et al., 1997). Once the initial activating signals are received 
through the T cell receptor (TCR) and CD28, it is believed that CD137 is 
upregulated, and subsequently interacts with APC-expressed CD137L. This in 
turn causes a signal to be transduced into the APC to enhance pro-inflammatory 
cytokine secretion, thereby providing additional co-stimulatory signals to the T 
cells; enhancing both clonal proliferation and survival in CD8+ T cells, and the 
latter in CD4+ T cells (Langstein et al., 1998; Lane et al., 1999; Langstein et al., 




Tumor necrosis factor receptor-associated factor (TRAF) 2 is an essential 
component and link to the various downstream signaling pathways of CD137, 
with the modulation of TRAF 1 (Jang et al., 1998). Activation of TRAF 2 by 
CD137 leads to its trimerization, which in turn activates the mitogen activated 
protein kinases (MAPKs). As detailed in Figure 4, the initial CD137 signal 
eventually results in the activation of jun-N-terminal kinase/stress-activated 
protein kinase (JNK/SAPK), and the p38 MAPK pathways (Dempsey et al., 
2003). Although the exact pathway linking the initial CD137 signal and nuclear 
factor-κB (NF-κB) is unclear, NF-κB inducing kinase (NIK) has been proposed to 
play a pivotal role in the activation of NF-κB. As a result, the expression of the 
anti-apoptotic proteins Bcl-XL and Bfl-1 are upregulated, and together with a 
signal from the TCR, CD137 is thus able to aid in the prevention of activation 
induced cell death (AICD), and costimulate interleukin (IL)-2 production 

































Figure 4. CD137 (4-1BB) signaling pathways. Diagram adapted from Watts et 
al (2005). 
 
1.7 STRUCTURE AND EXPRESSION OF HUMAN CD137 LIGAND 
CD137 ligand (CD137L, or 4-1BBL) is a type II transmembrane glycoprotein that 
belongs to the TNF superfamily, and is presumed to exist as a homotrimer (Smith 
and Baglioni, 1987; Rabu et al., 2006). The gene encoding human CD137L has 
been mapped to chromosome 19p13.3, with the protein itself comprising 254 aa 
(Alderson et al., 1994). 
 
CD137L is constitutively expressed by antigen presenting cells (APC), including  
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mature dendritic cells, monocytes and macrophages (Salih et al., 2000; Jung et 
al., 2004; Palma et al., 2004; Laderach et al., 2003; Lee et al., 2003). While some 
B cell lines also express CD137L constitutively, primary B cells only do so upon 
activation (Zhou et al., 1995; Palma et al., 2004). CD137L expression has also 
been observed in activated T cells, and some human carcinoma cell lines, notably, 
colonic, lung, breast, ovarian, and prostate (Laderach et al., 2003; Lee et al., 
2003; Schwarz, 2005).  
 
1.8 BIDIRECTIONAL SIGNALLING OF THE CD137:CD137L SYSTEM 
Like many other members of the TNFR superfamily, the CD137:CD137L system 
is capable of bidirectional signal transduction; the ability to transduce signals 
through both the receptor and its corresponding ligand (Schwarz, 2005). Reverse 
signaling, which specifically refers to signal transduction through the ligand, is 
possible as most TNF family members are expressed as membrane proteins with 
cytoplasmic domains (Lotz et al., 1996; Eissner et al., 2004). It is this 
bidirectional signaling capability that allows for extensive cross-talk to be 
mediated by the CD137:CD137L system, not only between many leukocyte 
subpopulations, but also between immune, and non-immune cells. Thus, in 
functional terms, these molecules would be described more aptly as co-receptors 




CD137L signal transduction into DCs is purported to enhance antigen 
presentation, by upregulating CD11c, CD80, CD86, and major histocompatibility 
complex (MHC) class II, as well as by increasing the production of IL-6 and IL-
12. (Kim et al., 2002; Futagawa et al., 2002; Laderach et al., 2003; Lippert et al., 
2008). As a result, the immune response mounted by DCs after CD137L 
crosslinking is enhanced. In the case of monocytes, CD137L signaling enhances 
proliferation and endomitosis, due to increased monocyte colony stimulating 
factor (M-CSF) secretion. Reverse signaling into monocytes also promotes 
adherence and secretion of proinflammatory cytokines such as TNF, IL-6, IL-8, 
and IL-12 (Langstein et al., 1998; Langstein et al., 1999; Langstein and Schwarz, 
1999). 
 
While the effects of CD137L signaling on APCs are costimulatory in nature, in T 
lymphocytes, the same reverse signaling is inhibitory; proliferation is reduced and 
apoptosis is increased (Schwarz et al., 1996). As CD137L expression on T cells is 
strictly activation-dependent, it has been postulated that the physiological function 
of this protein may be to down-regulate T cells when they are no longer required 






Figure 5. Bidirectional and reverse signaling of the CD137:CD137L system.  
Reverse signaling into APCs is activating in nature, while CD137L signal 
transduction into T cells induces apoptosis. Conversely, signaling via CD137 into 
T cells results in costimulation. Diagram adapted from Thum et al. (2008). 
 
Upon the cross-linking of the constitutively expressed CD137L on B lymphocytes 
by FDC-expressed CD137, B cell proliferation as well as Ig synthesis are 
enhanced (Pauly et al., 2002; Lindstedt et al., 2003). Apart from delivering 
growth and survival signals to the B cells via ICAM-1 mediated cell contact, 
FDCs also present antigens in the form of iccosomes to the B cells and play an 
essential role in the clonal selection of B cells with high-affinity B cell receptors 
(Pauly et al., 2002). Due to similarities to the CD40:CD40L system, which 
mediates T cell help to B cells after the first antigen encounter, the 
CD137:CD137L system may mediate co-stimulation of B lymphocytes during 




1.9 CD137/CD137L IN TUMOR IMMUNOTHERAPY 
As cell-mediated responses are essential for the elimination of cancer cells by the 
immune system, the immune evasion exhibited by tumors is often times 
frustrating. This immune evasion is generally accomplished by one or more of the 
following means: down-regulation of MHC I molecules, suppression of immune 
inhibitory molecule expression, and the total absence of recognizable tumor 
antigens (Cheuk et al., 2004). In order to circumvent these obstacles, numerous 
alternative strategies involving the activation of T cells, using co-stimulatory 
molecules of the B7:CD28 signaling pathway, have been developed. Since the 
effects of CD137:CD137L signal transduction are assumed to co-stimulate CD8+ 
T lymphocytes, thereby up-regulating the targeting of tumor cells, an increasing 
number of studies are starting to focus on the CD137:CD137L system as a viable 
candidate for anti-cancer immunotherapy. 
 
In the earliest murine models used, the eradication of established sarcoma and 
mastocytoma tumors following the direct injection of anti-CD137 monoclonal 
antibodies (mAbs) was observed (Melero et al., 1997). Equally encouraging are 
the many successes observed in numerous other murine models, and one of the 
latest phase I clinical trial of a humanized anti-CD137 mAb, even if most in vivo 
triumphs have not translated well into human clinical trials (McNamara et al., 
2008; Son et al., 2008). Anti-CD137 mAbs have also seen usage in combination  
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with mAbs against CD40 and TNF-related apoptosis inducing ligand (TRAIL), as 
well as, with engineered drug-resistant haematopoietic cells (Uno et al., 2006; 
McMillin et al., 2006). 
 
Apart from the direct injection of anti-CD137 mAbs, another approach that has 
been investigated is the adoptive transfer of T cells. In this technique, T 
lymphocytes were first costimulated ex vivo through the CD137 signaling 
pathway in conjunction with various other costimulatory molecules, and then 
adoptively transferred into mice. In the melanoma model used, a 60% cure rate 
was achieved, while in the fibrosarcoma model, survival was significantly 
prolonged (Strome et al., 2000). 
 
Various groups have also worked on developing whole cell vaccines against many 
different murine cancer models. Specifically, three main methods have been 
adapted for use. Firstly, cell lines were transduced with the CD137L gene and 
then injected into mice, resulting in the development of long term immunity 
against the wild-type tumor (Guinn et al., 1999; Guinn et al., 2001). Another 
approach involved the co-transfection of primary DCs with human CD137L and 
the tumor associated antigen (TAA) HER-2/neu, and using them as APCs in order  
to generate HER-2/neu-specific cytotoxic T lymphocytes (CTLs) (Grunebach et 
al., 2005). Lastly, single chains of Fv fragments of an anti-CD137 mAb gene 
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were transduced into the tumor cells, resulting in the vaccinated  mice rejecting 




Figure 6. Summary of CD137/CD137L in murine models of tumor immunotherapy. Diagram adapted from Cheuk et al. (2004). 
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1.10 MULTIPLE MYELOMA AND THE CD137:CD137L SYSTEM 
Thus far, no death domains, such as in CD95, death receptor (DR)4, and DR5, 
have been observed in the cytoplasmic regions of CD137 or CD137L, or even 
in the TNF/TNFR superfamily groups that CD137:CD137L system is 
classified together with (Croft, 2003). Hence, the use of CD137 or CD137L 
has traditionally been limited to the augmentation of the immune system, and 
not in the direct eradication of tumors. That is slowly changing, with reports 
emerging that present findings of apoptosis in resting primary T and B cells, 
and in anti-CD3 stimulated lymphocytes, by the direct action of the 
CD137:CD137L signal transduction pathway (Michel et al., 1998: Schwarz et 
al., 1996). 
 
In B cells however, current findings paint a vastly different picture; cross-
linking of B cell-expressed CD137L results in activation and an enhanced 
survivability, while CD137 on FDCs has been observed in contributing to an 
increased rate of survival of some B cell lymphomas (Park et al., 2004). 
Hence, it was assumed that the CD137L signal would also contribute to the 
enhanced and uncontrolled growth of MM cells, a B cell malignancy. 
Unexpectedly, preliminary results actually showed that the CD137L signal 
transduction resulted in an inhibition of proliferation, and even induced cell 
death, in the MM cell lines tested. If true, this data suggests that the cross-
linking of CD137L on MM cells might represent a novel method to 
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specifically target MM cells for destruction. 
 
1.11 MULTIPLE MYELOMA AND FOLLICULAR DENDRITIC  
       CELLS 
The majority of B cell lymphomas originate from the germinal centre 
(Kuppers et al., 1999), which is also where follicular dendritic cells (FDCs) 
are located. These germinal centre stromal cells are able to contribute to 
lymphoma generation by preventing apoptosis as well as by promoting the 
proliferation of transformed B cells. Tumorigenesis of these B cells can occur 
via selection for additional genetic changes or through adaptation to the 
protumorigenic environment provided by the FDCs; it is also probable that the 
FDCs provide the growth factors required for the metastasis of these cancer 
cells (Park and Choi, 2005). 
 
It has also been shown conclusively, via immunohistochemistry, that FDCs in 
the germinal center express CD137 strongly (Pauly et al., 2002). As 
previously mentioned, CD137:CD137L reverse signaling promotes 
proliferation in B lymphocytes and B cell lymphomas. Thus, the presence of 
CD137 on the FDCs might also indicate a similar proliferation inducing 
function for B lymphocytes. On this basis, it would appear that any interaction 
of B cell lymphoma cells, including MM, with CD137 expressing FDCs 
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should logically induce growth and survival. However, in direct contradiction 
to these facts, are the preliminary results showing that the effects of 
CD137:CD137L interaction in MM cells are in fact inhibitory in nature. 
 
In light of the above, it would be interesting to investigate the mechanisms 
behind this unforeseen occurrence. By isolating and immortalizing FDCs, if 
the same apoptotic effect is seen in the MM cell lines ex vivo, it might point to 
the presence of other factors, or perhaps even a synergistic effect only present 
in the germinal center microenvironment.  
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1.12 OBJECTIVES OF STUDY 
The specific objectives of this study are: 
a. to investigate the expression of CD137/CD137L on multiple myeloma 
cells 
b. to characterize the inhibitory effects of CD137 on multiple myeloma 
cells in detail 
c. to investigate the different effects of CD137 on multiple myeloma cells 
compared with other non-MM B cell lymphomas 
d. to develop an effective method of delivery for in vivo CD137 anti-MM 
therapy 
e. to generate a stable follicular dendritic cell line, followed by 
characterization of the CD137:CD137L signaling effects between 
FDCs and MM cells 
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2. MATERIALS AND METHODS 
All materials were purchased from Sigma-Aldrich (St Louis, MO) unless 
otherwise stated. 
 
2.1 CELL LINES 
The RPMI-8226 MM cell line, Raji, a Burkitt's lymphoma cell line, and 
Sp2/mIL-6, a transfected murine B cell line secreting murine IL-6, were 
obtained from ATCC (Manassas, VA, USA). The diffuse large B cell 
lymphoma lines, DOHH-2 and SUDHL-4, were obtained from the Deutsche 
Sammlung von Mikroorganismen und Zellkulturen GmbH (DSMZ, Germany). 
These five cell lines were routinely cultured in RPMI 1640 with 10% heat-
inactivated fetal bovine serum (FBS), henceforth referred to as RPMI-10 (refer 
to Appendix I).  
 
The newly established EBV-negative SGH-MM5 and SGH-MM6 human MM 
cell lines (CD10+, CD19-, CD20-, CD38+, CD40+, CD45+, CD56+, 
CD138+) were a generous gift from Dr Charles Gullo (Department of Clinical 
Research, Singapore General Hospital). The patient-derived MM cells were 
maintained in IMDM with 10% heat-inactivated FBS, henceforth referred to 




MM5-HS, the original SGH-MM5 cell line rendered HAT-sensitive by 
chronic administration of 8-azaguanine, was a gift from Dr Paul MacAry 
(Department of Microbiology, National University of Singapore). Similar to 
the original SGH cell lines, this HAT-sensitive cell line was also maintained in 
IMDM-10, with the addition of 5 µM 8-azaguanine. 
 
All of the above mentioned cell lines were passaged every 2-3 days and kept 
in a humidified incubator at 37oC with 5% CO2. 
 
2.2 RECOMBINANT PROTEINS AND ANTIBODIES 
The recombinant human CD137-Fc protein was purified from supernatants of 
stably transfected CHO cells by protein G sepharose, as described previously 
(Schwarz et al, 1996). Human IgG1 Fc fragment was purchased from 










Table 3. List of antibodies used 
Antibody Clone Source 
Mouse IgG1 κ isotype (PE-
conjugated) MOPC-21 
Sigma-Aldrich (St Louis, 
MO, USA) 
Mouse anti-human CD137 (PE-
conjugated) 4B4-1 
BD Pharmingen (Franklin 
Lakes, NJ, USA) 
Mouse anti-human 4-1BB ligand 
(unlabelled) 5F4 
Biolegend (San Diego, CA, 
USA) 




Mouse IgG1 κ isotype (unlabelled) MOPC-21 Sigma-Aldrich (St Louis, MO, USA) 
Goat anti-mouse IgG (PE-
conjugated) - 
Sigma-Aldrich (St Louis, 
MO, USA) 
Donkey anti-mouse IgG (PE-
conjugated) - 
eBioscience (San Diego, 
CA, USA) 
Mouse anti-human IgG (Fc-specific) GG-7 Sigma-Aldrich (St Louis, MO, USA) 
Mouse anti-human CD3 (FITC-
conjugated) UCHT1 
Biolegend (San Diego, CA, 
USA) 
Mouse anti-human CD14 (PE-
conjugated) 61D3 
eBioscience (San Diego, 
CA, USA) 
Mouse anti-human CD31 (FITC-
conjugated) WM59 
eBioscience (San Diego, 
CA, USA) 
Mouse anti-human CD303 (PE-
conjugated) AC144 Miltenyi Biotec (Germany) 





2.3 FLOW CYTOMETRIC ANALYSIS 
 
Aliquots of cultured cells (2-3 x 105) were stained with respective 
fluorochrome conjugated antibodies in phosphate buffered saline (PBS) 
containing 0.5% BSA and 0.1% sodium azide, hence forth referred to as 
FACS buffer (refer to Appendix II), for 1 h at 4oC in the dark. Cells were then 
washed twice with FACS buffer and resuspended in 400 μl FACS buffer. 
Flow cytometry was performed on a FACSort (Becton Dickinson, San Jose, 
CA) with CellQuest (Becton Disckinson) data acquisition and analysis 
software. Non-specific staining was controlled by isotype-matched antibodies. 
 
2.4 COATING OF CD137-Fc AND Fc PROTEIN 
Recombinant human CD137 protein was prepared as a fusion protein tagged 
with the Fc portion of human IgG1 molecule. Human IgG Fc protein and PBS 
were used as controls in all experiments.  
 
2.4.1 Coating on Plates 
96-well and 24-well plates (Nunc, Rosklide, Denmark) were coated with 50 μl 
and 500 μl, respectively, of CD137-Fc or Fc protein diluted in PBS to a final 
concentration of 10 μg/ml per well. The plates were then incubated at 4oC 
overnight, and the wells washed with PBS before addition of cells. 
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2.4.2 Coating on Beads 
SPHERETM Protein G-coated polystyrene particles (Spherotech, Lake Forest, 
IL) were incubated at 4oC overnight with 1.5 μg of CD137-Fc or Fc protein 
per 10 μl of beads. The beads were then washed twice with PBS before being 
plated into round bottom 96-well plates together with the cells. Plate-coated 
protein was used concurrently, and PBS-treated beads as the background 
control. 
 
2.4.3 Multimerization via Anti-Human Fc Antibody 
96-well plates were first co ated  with  5 0  µl o f 1 0  μg/ml o f an ti-human Fc 
antibody, clone GG-7, at 4oC overnight, before washing with PBS, and 
blocking with 100 µl FBS at 37oC for 1 h. 50 µl of 10 μg/ml of CD137-Fc or 
Fc protein were then added to the wells and incubated for a further 1 h at 
37oC, before the addition of the cells. 
 
2.5 DEATH AND APOPTOSIS ASSAYS 
Live and dead cell counts were performed with a haemocytometer after 
staining with trypan blue. Apoptotic and necrotic cells were stained by 10 
μg/ml ethidium bromide (EB) and 3 μg/ml acridine orange (AO) at a ratio of 1 
µl AO/EB solution per 106 cells, and viewed under the IX81 microscope 
(Olympus, USA).  
 32 
 
Annexin-V externalization was detected using the Annexin-V Apoptosis 
Detection Kit (BD Pharmingen, USA) according to the manufacturer’s 
protocols. In brief, cells were stained with Annexin-V and 7-
aminoactinomycin D (7-AAD) and left to incubate in the dark. Apoptotic 
analysis was then accomplished via flow cytometry and Summit 4.2 software 
(CyANTM, DakoCytomation, Denmark). 
 
2.6 PROLIFERATION ASSAYS 
Cells were pulsed with 0.5 μCi of [3H]-thymidine (Perkin Elmer, Waltham, 
MA, USA) for the last 16 h of the culture period. The cells were then 
harvested into a Packard Unifilter Plate using a MicroMate 196 Cell Harvester 
(Packard Instruments, Meridien, CT, USA) and dried at 56oC for 1-2 h, after 
which 20 μl of MicroScintTM solution (Perkin Elmer, Waltham, MA, USA),  
Radioactivity was measured using the TopCount liquid scintillation analyzer 
(Packard Instruments, Meridien, CT, USA). 
 
2.7 CELL CYCLE ANALYSIS 
Cells were first pelleted, followed by fixation and permeabilization by adding 
1.8 ml of cold 70% ethanol drop-wise, with continuous vortexing. Nucleic 
acid content in the cells were stained with 0.25 μg 7-AAD (BD Pharmingen,  
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USA) per 106 cells, for 10 min before flow analysis. Cell cycle analysis was 
performed on via flow cytometry (CyanTM, DakoCytomation, Denmark) and 
analyzed with ModFit LT software (Verity Software House, Topsham, USA). 
 
2.8 SANDWICH ELISA 
Levels of IL-6, IL-8, VEGF and TGF-β present in the cell culture supernatants 
were determined by human DuoSet ELISA Development Kits (R & D 
Systems, Minneapolis, MN), according to the manufacturer's protocol. All 
measurements were performed in triplicate. 
 
2.9 ISOLATION OF MM CELLS FROM PATIENT BONE MARROW  
      ASPIRATES 
Primary patient cells, which were a generous gift from Dr Chng Wee Joo 
(Department of Haematology-Oncology, National University Hospital), were 
derived from bone marrow aspirates taken from patients suffering 
frommultiple myeloma. CD138+ cells were isolated by using the MACS 
CD138+ Plasma Cell Isolation Kit (Miltenyi Biotec, Germany) according to 
the manufacturer's protocols. In brief, CD138-expressing cells were 
magnetically labelled with a monoclonal anti-human CD138 antibody, and 
then passed through a magnetic column. The CD138 enriched fraction was 
then eluted from the column. 
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2.10 GENERATION OF A STABLE, CD137-EXPRESSING    
        FOLLICULAR DENDRITIC CELL (FDC) LINE 
Tonsils were obtained from patients undergoing tonsillectomies courtesy of Dr 
Lynne Lim (Head Neck Surgery, National University Hospital). Only enlarged 
tonsils from otherwise healthy patients were utilized; inflamed tonsils were 
summarily rejected due to the elevated levels of activated T cells, which 
would also have expressed high levels of CD137. 
 
Two different methods were utilized in order to achieve immortalization of the 
cell line; transfection with telomerase-expressing vectors, and hybridization 






The pBABE-neo and pBABE-hTERT retroviral preparations were gifts from 
Dr Prakash Hande (Department of Physiology, National University of 
Singapore). Both plasmids contain the ampicillin resistance gene, and are 
selectable by neomycin. Transfection with pBABE-hTERT enables the 
expression of catalytic subunit of human telomerase, while pBABE-neo is its 
empty vector counterpart. Both vectors were amplified in Escherichia coli 
DH5α competent cells (Invitrogen, Carlsbad, CA, USA) before use. 
 
2.10.2 Preparation of Single-Cell Suspension from Whole Tonsil 
 
The whole tonsil was placed in a gentleMACS C Tube (Miltenyi Biotec, 
Germany) together with 3 ml of PBS containing 2 mM 
ethylenediaminetetraacetic acid (EDTA) and 0.5% BSA, henceforth referred 
to as MACS Buffer (refer to Appendix I). Additionally, 300 units/ml of 
Collagenase type IV (Worthington Biochemical, Lakewood, NJ), and 0.004% 
DNAse I (United States Biological, Swampscott, MA, USA), were included in 
the mixture. Tissue dissociation was accomplished with the aid of the 
gentleMACS Dissociator (Miltenyi Biotec, Germany), by running the preset 
spleen tissue dissociation protocol twice. The resulting cell suspension was 
filtered through a 30 µm cell strainer (BD Biosciences, San Jose, CA, USA), 




2.10.3 Selection of CD137-Expressing Cells 
Density gradient centrifugation with Histopaque®-1077, and CD3+ depletion 
via MACS CD3 MicroBeads, was first performed before selecting CD137+ 
cells utilizing the MACS CD137 MicroBead Kit (Miltenyi Biotec, Germany) 
according to the manufacturer's protocols.  
 
In brief, the cell suspension was overlaid on Histopaque®-1077 and 
centrifuged at 400g for 30 min. The interphase fraction was collected and used  
for CD3 depletion. CD3+ cells were magnetically labelled with a monoclonal 
anti-human CD3 antibody and passed through a magnetic column. The flow 
through was subsequently magnetically labelled with a monoclonal anti-
human CD137 antibody and again passed through a magnetic column. The 
bound cells were eluted, centrifuged at 300g for 10 min, and resuspended in 
Hepes-free RPMI-10 supplemented with 100 U/ml penicillin and 100 μg/ml 
streptomycin (Gibco Invitrogen, Carlsbad, CA). 
 
2.10.4 Transfection of CD137-Expressing Cells 
Transfection was performed using LipofectamineTM 2000 (Invitrogen, 
Carlsbad, CA) according to the manufacturer's protocol. A DNA: 
LipofectamineTM ratio of 1 μg : 1 μl was used for 107 cells per ml per 24-well 
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plate. Cells were transfected either with pBABE-hTERT, or with the empty 
vector pBABE-neo as control. 48 h post-transfection, selection antibiotics, in 
the form of 1 mg/ml Geneticin® (Gibco-Invitrogen, Carlsbard, CA, USA), 
was added and maintained for approximately 14 days, with medium changes 
every 3-4 days. 
 
2.10.5 Formation of FDC Hybridomas 
Two different HAT-sensitive cell lines were chosen for fusion with the CD3-
depleted, CD137-enriched tonsil cells: Sp2/mIL-6, as described previously 
(Harris et al, 1992), and MM5-HS. 
The CD137-enriched cells were mixed with the respective HAT-sensitive cell 
lines in a 3:1 ratio, and centrifuged to give a cell pellet. Cells were washed 
with Hepes-free RPMI 1640 media and centrifuged again. Subsequent steps 
were maintained at 37oC. The pellet was loosened by flicking the base of the 
tube. 1 ml of polyethylene glycol 1500 (Roche, Nutley, NJ, USA) was added 
per 108 cells and left to stand for 1 min. A total of 20 ml Hepes-free RPMI 
1640 media was then added very slowly, drop-wise and with constant 
agitation, in the following format: 1 ml in the 1st min, 4 ml in the 2nd min, and 
15 ml in the 3rd min. The fused cells are then centrifuged and gently 
resuspended in Hepes-free RPMI-10 supplemented with 100 U/ml penicillin, 




2.10.6 Selection of CD137-Expressing FDCs 
Both transfected cells and fused cells were left to grow at 37oC at 5% 
atmospheric CO2 and were selected over two weeks. In both cases, growth and 
confluency of the cultures indicated either a successful transfection or creation 
of a hybridoma. In order to sieve out any immortalized non-FDC cells, flow 
cytometry analysis was performed. 
 
Prospective immortalized FDCs were stained to check for the presence of 
CD14 (monocyte marker), and CD303 (DC marker), and the absence of CD3 
(T cell marker), and CD31 (endothelial cell marker). Additionally, the cells  
were sorted by fluorescence-activated cell sorting (FACS) after staining with 
an anti-human FDC monoclonal antibody, clone Ki-M4, and a PE-conjugated 
anti-mouse antibody. 
 
2.11 STATISTICAL ANALYSIS 
Statistical significance was determined by a two-tailed Student's t-test for both 




After initial results showed an unexpected inhibitory effect on MM cell 
growth and survival, preliminary experiments revolving around the 
characterization of the effects of CD137 on the proliferation and viability of 
the MM cell lines were planned. To establish a molecular basis for this 
premise, Section 3.1 details the expression profiles of both CD137 and 
CD137L on all six of the cell lines used. The following two sections go on to 
describe the inhibition of MM cell proliferation after treatment with CD137-
Fc, as well as CD137-induced cell death. These results suggest an induction of 
apoptosis in the CD137-treated MM cells. As the data presented in Section 3.4 
shows an up-regulation of pro-survival cytokines, experiments in the 
following section were subsequently planned to substantiate the hypothesis 
that these survival signals do not prevent CD137-induced apoptosis. Possible 
alternatives to enable immobilization of the recombinant CD137-Fc protein, so 
as to allow successful crosslinking of the CD13L, were also looked into, in the 
eventuality of moving into an in vivo test setting.  
 
As FDCs contribute to lymphoma generation by preventing apoptosis, and 
promoting the proliferation of transformed B cells, an immortalized FDC line 
would be an invaluable tool in the study of MM cell interactions. Thus, the last 





3.1 B CELL LYMPHOMA CELL LINES EXPRESS CD137L BUT NOT  
      CD137 
The molecular basis for B cells to receive costimulatory signals from CD137 
is the constitutive expression of CD137L by primary B cells (Jung et al., 2004; 
Zhou et al., 1995). Therefore, in any examination regarding the effects of 
CD137 on B cell lymphoma cell lines, the first step would be to determine 
CD137L expression. For this study, the Burkitt’s lymphoma Raji, the non-
Hodgkin’s lymphoma SUDHL-4, the B cell lymphoma DOHH-2, and the 
three multiple myeloma cell lines SGH-MM5, SGH-MM6, and RPMI-8226, 
were selected. All six cell lines express CD137L constitutively, but none of 
them expresses CD137 at any significant level (Figure 7), a situation identical 





Figure 7. CD137L is expressed by B cell lymphoma cell lines. Cells were 
stained with PE-conjugated monoclonal antibodies against CD137 (clone 4B4-
1), or anti-CD137L (clone 41B436), displayed as open histograms, or their 




































3.2 CD137 INHIBITS PROLIFERATION OF MM CELLS 
The reverse signal transduction activity of CD137 was tested in the B cell 
lines, as CD137L crosslinking has been shown to enhance the proliferation of 
preactivated B cells (Pauly et al., 2002; Pollock et al., 1994). Either 
monoclonal antibodies specific for CD137L, or a recombinant fusion protein 
consisting of the extracellular domain of CD137 and the constant domain (Fc) 
of IgG1 (CD137-Fc), were selected for use as tools to crosslink the CD137L 
on the cells. As negative controls, isotype-matched unspecific antibodies or a 
recombinant Fc protein were chosen, respectively. These proteins were 
immobilized onto tissue culture plates by coating the plates at 4oC overnight, 
to enable crosslinking of the CD137L on the lymphoma cells. 
 
No significant effect of CD137L stimulation on the proliferation of the Raji, 
DOHH-2, and SUDHL-4 cells over four days was observed, as assessed by 
3H-thymidine incorporation (Figure 8). In contrast, the proliferation of the 
three MM cell lines SGH-MM5, SGH-MM6, and RPMI-8226, was profoundly 
decreased by CD137, by as much as three-fold. This inhibitory effect was 
most visible at the final timepoint of 96 h (Figure 8). The lower count per min 
(CPM) figures exhibited by the MM cell line RPMI-8226 could be attributed 
to its lower proliferative index in general, as compared to the other, much 
































































































Figure 8. CD137 inhibits proliferation in MM, but not in non-MM cells. 
Cells were cultured on plates coated with 10 μg/ml of Fc or CD137-Fc protein 
or on uncoated plates (PBS). After the indicated times, proliferation was 
determined via 3H-thymidine incorporation. Depicted are means ± standard 
deviations of triplicate measurements. * p < 0.05, ** p < 0.01. This 




3.3 CD137 INDUCES CELL DEATH IN THE MM CELL LINES BY  
      APOPTOSIS  
The next question to be answered, in order to investigate the mechanism 
behind the inhibition of proliferation, was whether CD137L ligation of MM 
cells induced cell death. As exhibited clearly in Figure 9, the percentage of 
dead cells was increased up to two- to three-fold in MM cells after culturing 
for 72 h on CD137-Fc when compared to both Fc or PBS (Figure 9). Viability 
of the non-MM B cell lymphoma cell lines was not affected by CD137L 
signalling. 
 
In order to determine if the reduction in cell viability was due to CD137-Fc 
induced MM cell apoptosis, Annexin-V and 7-AAD staining was performed. 
This staining revealed significant increases in the percentages of both early 
apoptosis (Annexin-V+, 7-AAD-), and late apoptosis or necrosis (Annexin-V+, 
7-AAD+) after 24 h treatment with CD137-Fc (Figure 10). Apoptotic rates of 
the non-MM cell lines remained unchanged, consistent with the results from 
the proliferation and viability assays (Figures 8, 9). 
 
Induction of apoptosis was visually correlated by staining the cells with 
ethidium bromide and acridine orange. Extensive chromatin condensation and 
membrane blebbing, classical hallmarks of cells undergoing apoptosis, were   
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exhibited by the MM cells after treatment with CD137-Fc (Figure 11A, B). 
Cell cycle analysis further confirmed CD137-induced apoptosis by the 
appearance of a sub-G1 peak. In addition, the cell cycle analysis also revealed 

































































































Figure 9. CD137 induces cell death of MM, but not of non-MM cells. Cells 
were cultured on plates coated with 10 μg/ml of Fc or CD137-Fc protein or on 
uncoated plates (PBS). Cell viability was determined after 24, 48, 72, and 96 h 
via trypan blue staining. Depicted are means ± standard deviations of triplicate 
measurements. * p < 0.05, ** p < 0.01. This experiment is representative of 




Figure 10. CD137 induces apoptosis in the MM cell lines. SGH-MM5 cells at a density of 106 cells/ml were cultured on plates coated with 10 
μg/ml of Fc or CD137-Fc protein or on uncoated plates (PBS). After 24 h, the cells were stained with Annexin V and 7-AAD. Similar results 
were obtained for the other MM cell lines. 
MM cell lines










   
   






   

































   
   
   






   
   
   
   
















































Figure 11. CD137 induces chromatin condensation and membrane 
blebbing in MM cells. SGH-MM5 cells at a density of 106 cells/ml were cultured 
on plates coated with 10 μg/ml of Fc or CD137-Fc protein or on uncoated plates 
(PBS). (A) Cells were stained with Acridine Orange (green) and Ethidium Bromide 
(red). Photographs were taken at a magnification of 40x. (B) CD137-Fc treated SGH-
MM5 cells of B at a magnification of 200x. This experiment was performed three 
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Figure 12. CD137 induces apoptosis and cell cycle arrest in the S phase. 
Cells at a density of 106 cells/ml were cultured on plates coated with 10 μg/ml 
of Fc or CD137-Fc protein. Nucleic acid content in the cells were stained with 
7-AAD, and cell cycle analysis was subsequently performed. Dip G1, G2 and 
S refer to the diploid G1, G2 and S phases of the cell cycle. This experiment 
was performed three times with similar results.  
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3.4 ENGAGEMENT OF MM CELLS VIA CD137 RESULTS IN THE  
      EXPRESSION OF PRO-SURVIVAL CYTOKINES  
The processes of proliferation, survival and death of healthy and malignant B 
cell lymphoma cells are crucially influenced by cytokines. MM cells are no 
exception to this rule, in particular, IL-6 and IL-8 are important growth and 
survival factors, and their production is enhanced upon interaction of MM 
cells with BMSCs (Kline et al., 2007; Kawano et al., 1988; Kawano et al., 
1995). VEGF is crucial in regulating angiogenesis, while TGF-β is often 
secreted by tumor cells to blunt an anti-tumor immune response, or to increase 
the cells' threshold for the induction of apoptosis (Lauta, 2003; Chen et al., 
2001). 
 
Treatment with CD137L agonists promoted a strong up-regulation of both IL-
6 and IL-8 after 24, 48, or 96 h, that was not observed in the non-MM cell 
lines (Figures 13, 14). With the exception of IL-8 in RPMI-8226 cells, levels 
of these two cytokines were either below the detection limit or produced in 
negligible amounts in the control conditions. VEGF secretion was enhanced 
moderately in both the MM and non-MM cell lines by CD137-Fc (Figure 15), 
whereas levels of TGF-β were not affected significantly or uniformly (Figure 
16). The 10-fold higher increase of IL-6 secreted by RPMI-8226 cells, as 
compared to the other MM cell lines, could be attributed to the higher 
CD137L presence on the cellular membrane (Figure 7). Similarly, the 5-fold 
higher increase of TGF-β secreted by RPMI-8226 cells in comparison with its 
MM counterparts, could be due to the higher unstimulated basal level present. 
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Figure 13. CD137 upregulates IL-6 in MM, but not in non-MM cell lines. 
Cells at a density of 106 cells/ml were cultured on plates coated with 10 μg/ml 
of Fc or CD137-Fc protein. IL-6 concentrations in 24, 48, and 96 h cell 
supernatants were determined by ELISA. Depicted are means ± standard 
deviations from triplicate measurements. n.d. represents IL-6 levels below 



































































































Figure 14. CD137 upregulates IL-8 in MM, but not in non-MM cell lines. 
Cells at a density of 106 cells/ml were cultured on plates coated with 10 μg/ml 
of Fc or CD137-Fc protein. IL-8 concentrations in 24, 48, and 96 h cell 
supernatants were determined by ELISA. Depicted are means ± standard 
deviations from triplicate measurements. * p<0.05, ** p<0.01. This 













































































































Figure 15. CD137 upregulates VEGF in both MM and non-MM cell lines. 
Cells at a density of 106 cells/ml were cultured on plates coated with 10 μg/ml 
of Fc or CD137-Fc protein. VEGF concentrations in 24, 48, and 96 h cell 
supernatants were determined by ELISA. Depicted are means ± standard 
deviations from triplicate measurements. * p<0.05. This experiment was 



































































































Figure 16. CD137 has no effect on TGF-β production in both MM and 
non-MM cell lines. Cells at a density of 106 cells/ml were cultured on plates 
coated with 10 μg/ml of Fc or CD137-Fc protein. TGF-β concentrations in 24, 
48, and 96 h cell supernatants were determined by ELISA. Depicted are means 
± standard deviations from triplicate measurements. * p<0.05. This experiment 





















3.5 SURVIVAL SIGNALS DO NOT PREVENT CD137-INDUCED 
      APOPTOSIS OF MM CELLS  
The observation that CD137 treatment strongly induced up-regulation of IL-6, 
a potent MM survival factor, came as a great surprise, especially given its 
simultaneous induction of apoptosis in the MM cell lines. Therefore, an 
important next step was to determine if IL-6 interferes with the CD137L-
induced cell death. IL-2, the classical lymphocyte growth and survival factor 
was also included. 
Even in the presence of IL-6 or IL-2, treatment with immobilized CD137-Fc 
protein still triggered the induction of apoptosis in the MM cells. Neither 
cytokine was able to rescue the MM cells from CD137-induced apoptosis 
(Figure 17). In addition, blocking the IL-6 receptor by neutralizing antibodies 
had no effect on CD137-induced apoptosis in MM cells (personal 











Figure 17. CD137-induced MM cell death is not inhibited by IL-6 or IL-2. 
SGH-MM6 cells at a density of 1.2x106 cells/ml were cultured on plates 
coated with 10 μg/ml of Fc or CD137-Fc protein or on uncoated plates (PBS). 
Cell viability was determined after 24 h via trypan blue staining. Depicted are 
means ± standard deviations from triplicate measurements. * p<0.05. This 
experiment was performed three times with similar results. 
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3.6 REQUIREMENT OF IMMOBILIZATION OF CD137L AGONISTS 
As the addition of recombinant CD137-Fc protein in a soluble form showed no 
discernable effects on both the induction of cell death and the reduction of live 
cell numbers (Figure 18A), it was concluded that cross-linking of the CD137L 
was essential. There was also no observable difference in the numbers of live 
and apoptotic cells between uncoated wells (PBS) and Fc protein-coated wells, 
thereby demonstrating the lack of influence of the Fc control protein (Figure 
18B). 
 
In order to overcome the potential problem whereby CD137 crosslinking is 
rendered ineffective due to the protein not being immobilized and thereby 
undergo multimerization successfully, in both an in vivo and a clinical setting, 
the decision to attempt the immobilization of the CD137-Fc protein on 
microbeads was made. This is an especially vital component of the study, 
since without a means of immobilizing the protein, CD137-induced apoptosis 
would not occur. An alternative method, via the use of an anti-human Fc 
antibody to capture and thus to enable the multimerization of the recombinant 
CD137-Fc protein was also adopted. In both techniques, no significant 
induction of either MM cell death (Figures 19A, B), or IL-8 (Figures 20A, B) 
was observed. 


















































































Figure 18. Requirement of immobilization of CD137. SGH-MM5 (A and B) 
cells at a density of 106 cells/ml were cultured on uncoated plates (PBS), or on 
plates coated with 10 μg/ml of Fc, CD137-Fc, or to which Fc or CD137-Fc 
proteins were added soluble at 10 μg/ml. (A) Percentage of dead cells (left 
panel) and number of total live cells (right panel) were determined after 24 h 
via trypan blue staining. (B) Extent of apoptosis of cells in (A) was determined 
by Annexin V and 7-AAD staining. Depicted are means ± standard deviations 
of triplicate measurements. * p<0.05. These experiments are representatives of 



























































Figure 19. CD137 immobilized on beads or multimerized via α-Hu Fc 
mAb does not induce cell death in SGH-MM5 cells. SGH-MM5 cells at a 
density of 106 cells/ml were cultured on uncoated plates (PBS), or on plates 
coated with 10 μg/ml of Fc, CD137-Fc, for 24 h. Fc and CD137-Fc protein 
were also immobilized via (A)  protein G-coated beads (B) α-Hu Fc mAb 
(clone: GG-7). Depicted are means ± standard deviations of triplicate 
measurements. * p<0.05. These experiments are representatives of three 
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Figure 20. CD137 immobilized on beads or multimerized via α-Hu Fc 
mAb does not induce IL-8 production in SGH-MM5 cells. SGH-MM5 cells 
at a density of 106 cells/ml were cultured on uncoated plates (PBS), or on 
plates coated with 10 μg/ml of Fc, CD137-Fc, for 24 h. Fc and CD137-Fc 
protein were also immobilized via (A)  protein G-coated beads (B) α-Hu Fc 
mAb (clone: GG-7). Depicted are means ± standard deviations of triplicate 
measurements. * p<0.05. These experiments are representatives of three 
independent experiments with similar results. 
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3.7 GENERATION OF A STABLE, CD137-EXPRESSING FDC LINE 
To investigate and characterize the effects of CD137:CD137L signaling 
between FDCs and MM cells, CD137-expressing FDCs were first isolated 
from primary human tonsillar tissue, and then immortalized via two different 
methods; transfection and cell fusion. 
 
The selection of CD137-expressing FDCs was divided into three main phases; 
tissue dissociation, density gradient centrifugation, and magnetic cell sorting. 
After each phase, a sampling was taken and stained for a variety of cell 
markers. These markers included CD14, a monocyte/FDC marker, CD3, a T 
cell marker, CD31, an endothelial cell marker, KiM4, a FDC marker, as well 
as CD137. The samples were stained with both CD14 and KiM4 so as to help 
identify which fraction in each of the phases the FDCs were primarily isolated 
in. CD31 was chosen, as a literature review of previous FDC isolation 
protocols (Muñoz-Fernández et al., 2006; Kim et al., 1994) had revealed that 
endothelial cells co-isolated should also be in the same density gradient 
fraction as the FDCs. Lastly, staining was performed for CD137 and CD3 so 
as to ascertain the extent of activated T cell contamination.   
 
As the  cell isolation progressed, there was an enrichment of both CD14 and 
CD31-positive cells, indicating that the fraction chosen for sampling, and 
further isolation, very likely held the FDCs, as evidenced by the correlating 
presence of endothelial cells. While the increased percentage of CD137+ cells 
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was encouraging, the increased CD3+ population pointed towards a larger 
extent of activated T cell population, which as previously mentioned, would 
also express CD137 (Figure 21). KiM4 was not stained for to verify FDC 
enrichment, post CD137 magnetic selection, as it is a murine-produced 
antibody, similar to the PE-conjugated anti-CD137 mAb used to pull out the 
CD137+ cells. The anti-mouse PE-conjugated antibody would have labelled 
the anti-CD137 mAb as well, leading to a false positive result. 
 
Post-isolation, two techniques were employed in the immortalization of the 
FDCs. The first method involved the manipulation of cellular DNA via 
transfection, so as to allow the expression of the catalytic subunit of human 
telomerase. Cell fusion was the second technique performed. Fusion with two 
different HAT-sensitive cell lines to form hybridomas was carried out. Both 
transfected and fused cells were left to grow and were selected over two 
weeks. Unfortunately, in both cases, sorting and staining for the presence of 
KiM4 showed that none of the surviving cells post-selection were 
immortalized FDCs (data not shown). 
 
The isolation was performed thrice more. However, in order to reduce the 
amount of activated T cells present, only non-inflamed tonsils were used. An 
additional step whereby CD3+ cells were depleted by positive magnetic 
selection was also included in the protocol, prior to CD137+ magnetic 
selection. While this improved protocol resulted in cells that survived the 
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antibiotic selection process after transfection or fusion, the resulting cells were 
still not hardy enough to survive the sorting process. 
 
In summary, the objective of generating a stable, CD137-expressing FDC line 
was not accomplished. Although a streamlined and effective protocol for the 
isolation and enrichment of FDCs was formulated and proven, cell viability 
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Figure 21. Expression levels of CD137, CD14, CD3, CD31, and KiM4 in the samples after each phase of FDC isolation. Cells were stained 
with monoclonal antibodies against CD137 (clone 4B4-1), CD14 (clone 61D3), CD3 (UCHT1), CD31 (clone WM59), or KiM4 (clone KiM4), 




In this study, some unexpected activities of CD137L crosslinking on MM cell 
lines were identified. Some of these activities include the observations that 
CD137L reverse signalling inhibited proliferation, induced apoptosis and 
secretion of IL-6 and IL-8 selectively in the MM cell lines, but not in the non-
MM B cell lymphoma cell lines. 
 
These data comes as a surprise, especially since CD137 has been shown to 
enhance the activation and proliferation of primary B cells (Pauly et al., 2002; 
Pollok et al., 1994). Thus, it was a logical step in formulating the hypothesis 
that CD137 would also enhance the proliferation of B cell lines, even more so 
as CD137 can be expressed as a neoantigen by certain B cell lymphomas 
(personal communication, Thum E; unpublished data). In theory, the ectopic 
expression of CD137 could enable malignant B cells to send and receive 
growth and survival signals in an autocrine or paracrine manner, which under 
normal physiological conditions are delivered by CD137-expressing T helper 
cells, or follicular dendritic cells (Pauly et al., 2002; Lindstedt et al., 2003). 
 
In the following sections, a hitherto unrecognized role of CD137 and CD137L 
in MM cell biology will be elucidated and discussed, in particular, the 
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induction of apoptosis and the up-regulation of pro-survival cytokines. A 
potential underlying mechanism how CD137 induces cell death in MM cells 
will also be proposed. Alternate methods to enable successful CD137:CD137L 
crosslinking in an in vivo or clinical setting will be discussed as well. This will 
be followed by a dissection of the FDC isolation and immortalization process, 
as well as, an analysis of the advantages and implications derived in studying 
the interactions of MM cells and FDCs. Lastly, this chapter will conclude with 
suggestions for possible directions for future works.    
 
4.1 ACTIVATION INDUCED CELL DEATH AS A POSSIBLE   
      MECHANISM OF CD137-INDUCED CELL DEATH 
CD137L signalling induced the secretion of IL-6 and IL-8 specifically in the 
MM cell lines but not in the non-MM B cell lymphoma lines. VEGF is also 
induced by CD137L signals, albeit to a lower extent, and in both the MM and 
non-MM cell lines. IL-6 has been shown to be essential for MM growth and 
for protection from apoptosis (Kawano et al., 1988; Kawano et al., 1995), and 
increased IL-6 levels in MM patient sera correlate with disease progression 
(Lauta, 2003; Kabelitz et al., 1993). Similarly, IL-8 supports MM growth, and 
IL-8 secretion by bone marrow stromal cells also correlates with MM 
progression (Kline et al., 2007). VEGF is a potent growth factor for MM cells, 
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and supports MM growth by inducing angiogenesis (Dankbar et al., 2000; 
Podar et al., 2004). As all three cytokines listed above have been shown to be 
pro-survival cytokines in MM, these results are at first sight surprising, 
especially in the face of increased apoptosis rates in the MM cell lines tested. 
 
Secretion of pro-survival cytokines and NF-κB activation (personal 
communication, Schwarz H) clearly indicates cellular activation by CD137L 
signalling. A signal that is able to induce both cell death and activation at the 
same time seems to be a contradiction. A possible mechanism that might 
explain these conflicting effects could be due to activation-induced cell death 
(AICD), whereby the frequency of AICD is positively correlated to the degree 
of cell activation (Kabelitz et al., 1993). AICD is a well known phenomenon 
that has been described frequently in activated T cells, and to a lesser extent in 
B cells, at various stages of development after activation (Daniel et al., 1997; 
Berad et al., 1999; Dubravka and Scott, 2000).  
 
In B lymphocytes, AICD is a highly regulated event initiated by crosslinking 
of the B cell receptor (BCR), where the complex interplay between survival 
and death signals determines the B cell fate and, consequently, the immune 
response (Dubravka and Scott, 2000). In normal B cells, BCR crosslinking 
results in an initial activation of Src family members, followed subsequently 
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by a divergence of the BCR signaling pathway into several different signaling 
cascades, namely, phospholipase Cγ (PLCγ), Ras, and phosphotidylinositol-3 
kinase (PI3K) (Berridge, 1997). PLCγ activation by phosphorylation results in 
the release of the second messengers, inositol 1, 4, 5-triphosphate (IP3) and 
diacylglycerl, that mediate a small and sustained increase of cytosolic free 
calcium; essential for DNA synethesis, and subsequently, B cell proliferation 
to proceed (Yamada et al., 1993). A rapid elevation of cytosolic free calcium 
on the other hand, seems sufficient to induce growth inhibition and apoptosis 
in a variety of B cell lines (Muthukkumar et al., 1993; Genestier et al., 1994; 
Bonnefoy-Berad et al., 1994; Graves et al., 1996). The second signal 
transduction cascade initiated by BCR crosslinking is mediated by Ras 
activation, whereby a sequential phosphorylation cascade, involving Raf-1, 
MAPK/Erk kinase (MEK), and mitogen-activated protein kinase (MAPK), is 
activated. Subsequent translocation of MAPK into the nucleus then induces 
transcription, or in some cases, might be required for the induction of 
apoptosis (Graves et al., 1996). Finally, the activation of the Src family 
kinases leads to PI3K activation, which in turn phosphorylates 
phosphotidylinositol 4, 5-bisphosphate (PIP2), leading to the 
phosphotidylinositol 3, 4, 5-triphosphate (PIP3) second messenger. The 
downstream target of PI3K, PKB/Akt then acts upon p70S6K, an enzyme 
implicated in mRNA translation (Fruman et al., 1998; Campbell, 1999). 
Inhibition of the PI3K pathway on the other hand, has been shown to induce 
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G1 arrest and apoptosis, alluding to a correlation between BCR-mediated 
inactivation of PI3K/p70S6K pathway and BCR-mediated apoptosis (Carey and 
Scott, 2001). For the sustained proliferation upon the engagement of the BCR, 
a second co-stimulatory signal, that is provided by T helper cells, is needed. 
Without this second signal, BCR engagement results in abortive activation, 
anergy, or deletion (Parry et al., 1994). In conclusion, extensive BCR 
stimulation can lead to either B cell proliferation, in the presence of a co-
stimulatory signal, or growth arrest and apoptosis/AICD in the absence of T 
cell help. 
 
The fact that MM cells are not rescued from CD137L agonist-induced cell 
death, by the addition of IL-2 or IL-6, also supports AICD as a viable 
hypothesis. Another factor in favour of the AICD hypothesis, is that this same 
mechanism has been suggested as the most plausible explanation for anti-
CD40 induced B cell death (Funakoshi et al., 1994; Szocinski et al., 2002). 
CD40 shares many similarities with CD137, and indeed, anti-CD40 antibodies 
have been shown to have a direct cytotoxic effect in various B cell 
malignancies, including in MM (Tai et al., 2004; Law et al., 2005). Finally, 
CD40 stimulation, similar to CD137 ligand, has been shown to induce 
apoptosis or proliferation in different cell types despite the activation of the 
NF-κB pathway in both instances (Vonderheide et al., 2007). Phase I clinical 
trials with CD40 agonists are currently being conducted on MM patients with 
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encouraging results (Vonderheide et al., 2007), and while the exact 
mechanism of anti-CD40 induced B cell death is not know, AICD has been 
one of the mechanisms postulated to be at the root of it. 
 
Both the MM and non-MM cell lines expressed similar levels of CD137L. The 
observation of an enhanced VEGF secretion in both cell line types after 
CD137L crosslinking demonstrates that the CD137 reverse signalling pathway 
is also functional in the non-MM cell lines. Inhibition of proliferation, 
induction of apoptosis, and IL-6 and IL-8 secretion however, were specific to 
the MM cell lines. Although the molecular basis of this difference in 
biological responses between the MM and non-MM cell lines is still unknown, 
a possible explanation could be provided by the recent finding that many MM 
tumors have NF-κB constitutively activated (Keats at al., 2007; Annunziata et 
al., 2007). Thus, any additional stimulation, for example by CD137 or by anti-
CD40 antibodies, may therefore induce AICD in MM cells, especially when 
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both the CD137 ligand and CD40 signalling systems are known to be part of a 
group of co-stimulatory molecules known to activate B cells (Pauly et al., 
2002). 
As AICD may take place when the surrounding environment is favourable for 
cell survival and proliferation (Szocinski et al., 2002), this would explain why 
the upregulation of pro-survival cytokines like IL-6 and IL-8 after CD137-Fc 
treatment is not able to prevent cell death. The effects, shown previously, of 
CD137-Fc treatment on MM cells could suggest that the CD137:CD137L 
system may help to regulate the activity and survival of normal, terminally 
differentiated plasma cells in the bone marrow. Excessive signalling through 
CD137L might result in plasma cells undergoing apoptosis in the form of 
AICD, as plasma cells by nature usually have a short lifespan of two to three 
days. Although this might point to why MM cells die when treated with 
CD137-Fc, there is no data currently available showing the effects of CD137 
reverse signalling on primary plasma cells. Neither has the expression of 
CD137 in the bone marrow microenvironment been shown previously. 
Therefore, more work has to be done in these areas to prove the theory of 
CD137-induced MM cell death as AICD and that this phenomenon occurs in 




4.2 CD137L AGONISTS NEED TO BE IMMOBILIZED IN ORDER  
      FOR THE INDUCTION OF CELL DEATH 
 
All of the experiments depicted in the previous section, required the 
immobilization of the CD137-Fc protein onto tissue culture plates for 
successful crosslinking of the CD137L on MM cells, and thus enabling the 
induction of cell death. Initially, it was thought that immobilization of the 
protein merely served as a way to concentrate the CD137, allowing a lower 
concentration to be used than otherwise needed. In this way, all one would 
need to deliver the CD137-Fc, would be a simple injection at the site of 
interest. However, attempts to replicate CD137-induced apoptosis were 
unsuccessful when the CD137-Fc protein was added into the culture medium 
soluble. This poses a pretty grave problem when the experiments are moved 
into an in vivo setting.  
 
Thus, two alternatives were tested out in an attempt to circumvent this 
problem. Namely, immobilization on microbeads, and multimerization of the 
CD137 protein via an α-Hu Fc mAb. However, as shown in the section above, 
both methods did not yield any significant induction of cell death, or secretion 
of IL-8. Observation of the MM cells under magnification, via the use of a 




The failure of the CD137-coated microbeads to increase the apoptotic rates in 
the MM cells could be postulated to be due to a low efficiency of protein 
adsorption onto the beads. This was unlikely, as there have been many reports 
in the past few decades demonstrating the use of microbeads to bind various 
proteins by simple adsorption (Wide and Porath, 1966; Weliky and Weetall, 
1965; Monthony et al., 1977; Jolley at al., 1984). What might have happened, 
which is also outlined as a point of caution in the manufacturer’s technical 
notes, was that leaching of the coated CD137-Fc protein might have occurred. 
And as shown earlier, this would have resulted in a much higher proportion of 
soluble CD137 than assumed, resulting in a loss of successful CD137:CD137L 
signalling and thus a decrease in MM cell death. Thus, in future experiments, 
it would be wise to bind CD137-Fc covalently, to ensure a more permanent 
and stable immobilization. From this reasoning, one might therefore infer that 
a certain signalling threshold would have to be exceeded, before the inhibitory 
effects of CD137 can be observed. 
 
Although efforts were made to ensure a good mix of CD137-coated beads and 
MM cells by pipetting the mixture thoroughly, the establishment of a 
consistent contact geometry between microbeads and cells could not be 
confirmed. Based on previous reports (Wei et al., 1999; Puig-de-Morales et 
al., 2004), this lack of a precise contact geometry might have resulted in a 
spatial orientation mismatch of the CD137 and CD137L. Thus, the spherical 
 73 
 
architecture of the beads, as compared to the relatively flat surface of the 
bottom of a cell culture plate well, itself might have limited the actual density 
of CD137-Fc available to crosslink the CD137L expressed on the MM cells. 
This might have been compounded by the fact that the size of the microbeads, 
at a diameter of 4 μm, would have provided a much smaller contact surface 
area for CD137:CD137L crosslinking. The actual contact area between the 
MM cells and the microbeads would most likely also be smaller than the 
apparent contact area, considering the local roughness of the cell surface. 
Therefore, some portion of the CD137 protein coated on estimated contact 
area might not have been able to reach the CD137L molecules, despite 
favourable diffusion. 
 
Previously, it had been shown that 3 μm and 1 μm bead diameter thresholds 
were essential for effective antigen-dependent degranulation and integrin-
mediated adhesion of cytotoxic T lymphocytes, respectively (Mescher, 1992; 
Ganpule et al., 1997). Thus based on the available literature, it was assumed 
that a 4 μm diameter microbead would have provided sufficient contact area 
for successful CD137:CD137L crosslinking. The minimal contact area 
required might correspond to a spatial limit for recruiting CD137L and/or 
other signal transduction molecules (Wei et al., 1999). In order to ensure 
sufficient contact, one might have to increase the size of the beads used. But 
this would bring another problem into the foreground; any bead size larger 
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than 4 μm would cause problems with regards to delivery into the site of 
interest in an in vivo setting, as it could clog capillaries.  Therefore, it appears 
that another alternative needs to be found for a successful in vivo 
CD137:CD137L crosslinking. 
 
Next, an attempt was made to multimerize the CD137-Fc protein via the use of 
an α-Hu Fc mAb. This experimental step was supported by previous literature 
showing that two trimeric Fas ligands or CD40 ligands were sufficient to 
trigger apoptosis or B cell proliferation, respectively, and that a higher degree 
of multimerization further enhanced CD40 ligand stimulation (Holler et al., 
2003). This was also supported by data showing that two cross-linked 
CD137L trimers were sufficient to trigger co-stimulatory signals, with a 
higher degree of oligomerization leading to enhanced co-stimulation (Rabu et 
al., 2005). Hence, the higher-order multimerization of the ligand, previously 
achieved by the direct immobilization of the CD137 protein to the tissue 
culture plates, was replicated by using an α-Hu Fc mAb to capture the CD137-
Fc. 
 
Since an induction of MM cell death or IL-8 was not obtained, a logical 
assumption would be that the α-Hu Fc mAb had failed to multimerize the 




portion of human IgG, had also been previously successfully immobilized 
onto cell culture plates for use in cell adhesion assays, via an anti-human IgG 
antibody, demonstrating that this technique does in fact work (Mizuno et al., 
1997). Additionally, an ELISA testing for the presence of sCD137 in the 
coating supernatant, after incubation with the α-Hu Fc mAb, also revealed an 
expected and corresponding drop in CD137 levels (data not shown), thereby 
demonstrating the successful capture of the CD137-Fc by the α-Hu Fc mAb 
onto the cell culture plate.  
 
Due to the specificity of the antibody to the Fc region of the recombinant 
protein, it is unlikely that the CD137-Fc is being multimerized in such a way 
that it would block the CD137:CD137L interaction. But the mAb might 
multimerize the CD137-Fc in such a way that the density of the recombinant 
protein might not be sufficient to trigger an apoptotic signal. Theoretically, 
each of the binding domains on the α-Hu Fc mAb should be able to bind one 
molecule of CD137-Fc. However, not all of the Fc domains in CD137-Fc may 
be simultaneously available for binding. What could be happening is that 
when a CD137-Fc molecule is captured by one of the anti-Hu Fc antibodies, it 
might be sterically blocking the access of another CD137 molecule to an 
adjacent Fc-binding domain. Another possibility is that the CD137 molecules 
that are bound by one anti-Hu Fc mAb molecule might be hindering other 
CD137-Fc molecules from being captured by an adjacent α-Hu Fc mAb on the 
cell culture plate (Ghose et al., 2006).  
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4.3 TROUBLESHOOTING IMPROVEMENTS MADE AND     
      RECOMMENDED IN THE ISOLATION AND  
      IMMORTALIZATION OF FDCs  
 
To investigate the effects of FDC on CD137:CD137L reverse signalling in 
MM cells, an enriched FDC fraction was prepared from human tonsillar tissue. 
The protocol adopted for use in the FDC isolation, consisted of commonly 
used methods, including the enzymatic digestion of the tonsillar tissue 
followed by centrifugal separation through Percoll or BSA (diluted in PBS to 
form specific density layers) density gradients. With the use of a specific α-Hu 
FDC mAb, it is possible to obtain a 95% homogeneous FDC fraction via cell 
sorting (Kim et al., 1994). However, the number of FDCs purified in this way, 
would have been insufficient to perform any experiments extensively. 
Furthermore, it would have been extremely difficult to dissociate in vivo 
bound B cells from the freshly isolated FDCs. Therefore, in order to surmount 
these obstacles, it was decided to establish a FDC cell line to facilitate this 
process. 
 
Digestion was performed with type IV collagenase instead of other 
recommended enzymes so as to preserve the structural integrity of the CD137 
expressed on the FDC cell surface. DNAse I was added in subsequent 
isolations to decrease the viscosity of the enriched fractions. Both Percoll and 
 77 
 
BSA density gradient centrifugations were carried out, but cell separation via 
Histopaque was eventually chosen, both for fractions that were visibly more 
separated, as well as for convenience of preparation. 
 
For the first two isolations, tonsillar tissues were used without consideration of 
their inflammation status. Upon discovering the extent of activated T cell 
contamination within the enriched FDC population, it was decided that only 
non-inflamed tonsils would be used. In addition, an extra step was taken to 
limit the levels of CD137-expressing, activated T cells by performing a CD3 
magnetic assisted depletion prior to the CD137 positive magnetic selection. 
Although recommended, cell sorting was not immediately carried out before 
immortalization of the FDCs, as a visual inspection under microscopic 
magnification had revealed that the FDCs were not as numerous or as healthy 
as hoped for. Hence, immortalization of the FDCs was performed, and the 
cultures left to expand, in the hope that cell sorting would then become a 
viable option. 
 
Although one of the aims of this project was to generate a stable FDC cell line, 
followed by characterization of the CD137:CD137L signalling effects between 
FDCs and MM cells, the isolation and immortalization protocols were not as 
successful as hoped for. In addition, the use of the HAT-sensitive multiple 
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myeloma cell line, MM5-HS, would seem contradictory to this aim. Since 
CD137 has already been shown to induce apoptosis in MM cells, it would 
seem counter-intuitive to attempt a cell fusion of CD137-expressing FDCs 
together with a CD137L-expressing MM cell line. The implications of doing 
so did not go unnoticed. The selection of this MM cell line was in part due to 
its ready availability, as well as a stop-gap measure in lieu of an appropriate 
cell line. Eventually, the Sp2/mIL-6 cell line was obtained and used in place 
accordingly, as previously described (Harris et al., 1992). 
 
A major reason for the failure to successfully generate a stable CD137-
expressing FDC cell line could be attributed to the low numbers of isolated 
FDCs. In each of the tonsillectomies, only one tonsil sample was accessible 
for use. Based on the fact that the percentage of FDCs in human tonsillar 
tissue only ranges from 5 to 8% (Sprenger et al., 1995), and the small mass of 
each tonsil, it would be highly difficult to extricate sufficient quantities of 
viable FDCs for use, even assuming a 100% rate of isolation. The use of both 
tonsils would logically double the number of FDCs obtained, and greatly 




4.4 ADVANTAGES AND IMPLICATIONS IN STUDYING THE  
      INTERACTIONS BETWEEN B CELLS, MM CELLS AND FDCs 
FDCs trap immune complexes with their abundant complement and Ig Fc 
receptors within the B-cell follicles, a critical process in the development of 
high-affinity, isotype-switched Ab responses (Tew et al., 1997). FDCs play 
important roles in germinal centre (GC) B cell proliferation, survival, and 
differentiation in both antigen-dependent and independent manners (Burton et 
al., 1993, Tew et al., 1997). FDCs also seem to supply numerous non-specific 
stimuli during GC responses for the generation of an optimal B cell response 
(Kosco-Vilbois, 2003), as well as, various potent accessory signals to prevent 
apoptosis and aid in B cell selection during receptor affinity maturation 
processes (Imal and Yamakawa, 1996; Szabo et al., 1997; Liu et al., 1989; 
Koopman et al., 1994; Kosco et al., 1992). The finding that FDCs express 
high levels of CD137 on the cell surface, is not only in agreement with recent 
data exhibiting the effects of CD137 on the activation of GC B cells (Pauly et 
al., 2002), it also represents an additional way for the FDCs to interact with 
both the CD137L-expressing GC B cells (Lindstedt et al., 2003) and MM 
cells.  
 
Interestingly, both T cells and FDCs, the two main regulators of the humoral 
response, have been shown to express CD137. T cells regulate the B cell 
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response by activating the proliferation and differentiation of B cells, as well 
as, eliminating autoreactive B cell clones, while FDCs present antigens and 
allow for the selection of high-affinity clones (Hollmann and Gerdes, 1999). 
In addition to providing survival signals, some FDCs have also been shown to 
express FasL, and may also participate in the apoptosis of GC B cells (Hur et 
al., 2000). In the light of these findings, and of the results presented above 
showing CD137-induced apoptosis in MM cells, a malignancy of B cell 
origin, it would therefore be interesting to determine if FDC-expressed CD137 
is able to either compound, or rescue MM cells from CD137-induced cell 
death. 
 
Notch signalling regulates cell fate during development and differentiation in 
many cell lineages, including lymphocytes (Artavanis-Tsakonas et al., 1999). 
It has been reported that Notch signalling plays critical roles in B cell 
development (He and Pear, 2003). In addition, recent data has also provided 
the observation that Notch signalling is able to affect the activation and 
differntiation of mature B cells to antibody-secreting cells (Thomas et al., 
2007; Santos et al., 2007), revealing the importance of Notch signalling to the 
generation of plasma cells, and possibly MM cells. FDCs have been shown to 
not only express Notch ligands, but recent data has also pointed to the 
protection of GC B cells from apoptosis by Notch signalling (Yoon et al., 
2009). Since the data presented above have already shown the apoptosis-
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inducing effects of CD137 on MM cells, Notch signalling might provide a 
molecular basis to understanding FDC-MM cell interaction, in the event that a 
CD137-expressing FDC cell line is unable to induce MM cell death.  
 
These observations on Notch signalling may have significant implications in 
treating B cell lymphomas, including multiple myeloma. The majority of B 
cell lymphomas originates from the GC (Stevenson et al., 1998), in particular, 
follicular lymphoma, nodular lymphocyte predominant Hodgkin’s lymphoma, 
and classic Hodgkin’s lymphoma (Carbone et al., 2009), and remains 
dependent on the GC microenvironment (Petrasch et al., 1992). It has been 
speculated that stromal microenvironments may contribute to the development 
of drug resistance in B cell lymphomas (Bohen et al., 2003). On the other 
hand, although no studies have been conducted to date with regards to the 
effect of Notch signalling on MM cells, it might yet turn out that targeting 
both the CD137 and Notch signalling pathways deserves consideration as 
candidates for the treatment of multiple myeloma, in combination with current 
therapies.  
 
Cross-linking of CD137L by CD137 has been shown to induce apoptosis in 
lymphocytes (Schwarz et al., 2006; Michel et al., 1999). In a transgenic 
murine model, where CD137L was exclusively produced by APCs, T cell 
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numbers remained unchanged, whereas B cells were depleted. No B cell 
follicles could be detected either. The increased interaction between CD137-
expressing FDCs and CD137L-expressing B cells may have resulted in an 
enhanced depletion of B cells, and thus lack of formation of follicles 
(Lindstedt et al., 2003). These results are in direct contradiction to previous 
data where CD137:CD137L interaction results in B cell proliferation. 
Therefore, functional studies concerning the CD137:CD137L signalling are 
important for better understanding of the interaction between FDCs, B cells, 
and MM cells. Hence, the generation of a CD137-expressing FDC cell line is 







4.5 FUTURE WORKS 
 
 
4.5.1 Synergistic Effects of CD137 and Chemotherapeutic Drugs on MM  
          Cell Death 
 
In addition to treating the MM cell lines with CD137-Fc, the culture media 
will also include various concentrations of chemotherapeutic drugs such as 
thalidomide, dexamethasone, and doxorubicin. Lactate dehydrogenase (LDH) 
assays will then be conducted as a readout of cell death.  
 
4.5.2 Verification of Key Results with Patient MM Cells and Healthy B 
          Cells 
For validation of the observations made with the MM cell lines, MM patient 
plasma cells will be extracted from bone marrow aspirates, while B cells from 
healthy volunteers will be isolated from their buffy coat.  
 
4.5.3 Identifying Mechanisms and Signalling Cascades Involved in MM  
         Cell Migration 
 
A major problem in multiple myeloma is the migration of malignant cells from 
the blood to the bone marrow, the accumulation of MM cells in the bone, and 
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their destruction of healthy bone tissue. Although very little is known about 
the signals that lead to this aberrant migration, Rho family GTPases have been 
shown to play a pivotal role in the migration and attachment of leukocytes. To 
this end, the function of Rho GTPases will be characterized, as well as, 
determining if CD137 interferes with MM cell migration and signalling.  
 
4.5.4 Development of a Formulation of CD137 for in vivo  Experiments 
Soluble CD137-Fc shows little to no effect in the inhibition of MM cell lines. 
The above data has also shown that both the immobilization of CD137 on 
microbeads or its capturing via α-Hu Fc mAbs are not viable options. An 
alternative would be to employ a "Cell-Ghost", where a CD137-expressing 
cell line is incubated in a hypotonic solution. Upon bursting of the cell, its 
intracellular contents are released. Passage through a magnetic column would 
then ensure that only the membrane, with all of its associated proteins, 
including CD137, is selected, forming the "Cell-Ghost". 
 
4.5.5 Murine MM Models 
Two different models will be considered for the in vivo phase of the 
experiments; a xenograft and human bone chip SCID mouse MM model. 
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These models will hopefully aid in the determination of the inhibitory effects 
of CD137 on MM cell growth in vivo. 
 
SGH-MM5 or SGH-MM6 cells will be injected subcutaneously into nude 
mice (Epstein and Yaccoby, 2005). Upon tumor development, one group of 
mice will be treated with the in vivo formulation of immobilized CD137-Fc. 
Two other groups will be treated with the control Fc protein and normally 
immobilized CD137-Fc respectively. Tumor growth will be checked and 
measured, while the effect of CD137 or anti-CD137L mAb treatment will be 
evaluated in a Kaplan-Meyer plot. 
 
Although technically more demanding, the human bone chip SCID mouse 
MM model is physiologically more accurate, as it allows the MM cells to 
interact with the bone marrow microenvironment that is essential for human 
MM growth (Tassone et al., 2005; Harousseau et al., 2004). Femurs and tibia 
from week 19 to 23 gestational foetuses will be implanted subcutaneously into 
both hind flanks of 6 to 8 week old SCID mice (McCune et al., 1988).  Four 
weeks later, MM cells will be labeled by transfection with green fluorescent 
protein (GFP), and injected directly into the right flank human bone chip 
implant, while PBS is injected into the left implant. At two week intervals 
after treatment, the mice will be evaluated for MM proliferation and 




CD137 treatment of MM cells inhibits proliferation and induces cell death via 
apoptosis. This happens despite the induction of the pro-survival cytokines IL-
6 and IL-8. Since CD137 functions as a co-stimulatory molecule on B cells, 
the results presented above suggest AICD as a possible mechanism of cell 
death. In addition, the significant inhibitory effects exerted by CD137 are 
exclusively seen with MM cell lines, and not with non-MM B cell lymphoma 
lines. If a similar selective targeting and elimination of MM cells in patients 
could be achieved, that could help to slow down the progression of the 
disease. It could also be used in conjunction with conventional treatment 
regimes such as thalidomide and dexamethasone, and thereby allowing a 
reduction in the dose of chemotherapy and hence reduced side effects. A 
reduction in the dosage needed to achieve efficacy would allow patients to 
lengthen their use of therapeutic agents while reducing the frequency and/or 
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APPENDIX I - MATERIALS FOR CELL CULTURE 
1. Iscove's Modified Dulbeccos Medium (IMDM) 
To prepare 1L of media: 
Item Quantity Source 
IMDM powder 17.7 g Sigma-Aldrich (St Louis, MO) 
L-glutamine (100x) 10 ml Gibco, Invitrogen (Carlsbad, CA) 
Sodium bicarbonate 3.02 g US Biological (Swampscott, MA) 
MiliQ water 1 L - 
 
The medium was then sterile-filtered through a 0.22 μm filter membrane. 
2. IMDM-10 
To prepare 500 ml of media: 
Item Quantity Source 
IMDM media 450 ml - 





To prepare 1L of media: 
Item Quantity Source 
RPMI powder 16.35 g Sigma-Aldrich (St Louis, MO) 
L-glutamine (100x) 10 ml Gibco, Invitrogen (Carlsbad, CA) 
Sodium bicarbonate 2.0 g US Biological (Swampscott, MA) 
MiliQ water 1 L - 
 
The medium was then sterile-filtered through a 0.22 μm filter membrane. 
4. RPMI-10 
To prepare 500 ml of media: 
Item Quantity Source 
RPMI-1640 media 450 ml - 
Foetal Bovine Serum 50 ml Biowest (Nuaville, France) 
 
5. Phosphate Buffered Saline (PBS) 
To prepare 1 L of solution: 
Item Quantity Source 
NaCl 8 g Sigma-Aldrich (St Louis, MO) 
KCl 0.2 g Sigma-Aldrich (St Louis, MO) 
Na2HPO4 1.44 g Sigma-Aldrich (St Louis, MO) 
KH2PO4 0.24 g Sigma-Aldrich (St Louis, MO) 
MiliQ Water 1 L - 
 
The solution was sterilized by autoclaving after its pH was adjusted to 7.4.  
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6. MACS buffer 
To prepare 1 L of buffer: 
Item Quantity Source 
PBS 1 L - 
Bovine Serum Albumin 5 ml Biowest (Nuaville, France) 
EDTA 4 ml 1st Base (Singapore) 
 





APPENDIX II - MATERIALS FOR FLOW CYTOMETRY   
                            AND ELISA 
 
1. FACS buffer 
To prepare 500 ml of buffer: 
Item Quantity Source 
FBS 2.5 ml Biowest (Nuaville, France) 
NaN3 0.1 g Sigma-Aldrich (St Louis, MO) 
PBS 500 ml - 
 
2. 0.05 M Phosphate Citrate buffer (for TMB substrate solution) 
To prepare 100 ml of buffer: 
Item Quantity Source 
0.2 M Na2HPO4 solution 25.7 ml Sigma-Aldrich (St Louis, MO) 
0.1 M citric acid 24.3 ml Sigma-Aldrich (St Louis, MO) 
 
The pH of the solution was adjusted to 5.0, and the volume was topped up to 
100 ml with MiliQ water. 
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3. TMB substrate solution 
To prepare 10 ml of solution: 
Item Quantity Source 
TMB tablet 1 tablet Sigma-Aldrich (St Louis, MO) 
0.05 M phosphate citrate 
buffer 10 ml - 
30% H2O2 2 μl Kanto Chemicals (Japan) 
 
4. PBST 
To prepare 1 L of solution: 
Item Quantity Source 
Tween-20 500 μl Bio-Rad (Hercules, CA) 
PBS 1 L - 
 
 
